Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy INmune Bio stock | $19.05

Learn how to easily invest in INmune Bio stock.

INmune Bio Inc is a biotechnology business based in the US. INmune Bio shares (INMB) are listed on the NASDAQ and all prices are listed in US Dollars. INmune Bio employs 5 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in INmune Bio

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – INMB – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

INmune Bio stock price (NASDAQ: INMB)

Use our graph to track the performance of INMB stocks over time.

INmune Bio shares at a glance

Information last updated 2021-10-24.
Latest market close$19.05
52-week range$7.28 - $30.37
50-day moving average $19.30
200-day moving average $16.77
Wall St. target price$32.75
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.37

Buy INmune Bio shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Robinhood
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
N/A
$20 per year
N/A
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
TradeStation
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Moomoo
Stocks
$0
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy INmune Bio stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

INmune Bio price performance over time

Historical closes compared with the close of $19.05 from 2021-10-25

1 week (2021-10-19) 4.38%
1 month (2021-09-24) -5.41%
3 months (2021-07-26) 17.45%
6 months (2021-04-26) 60.35%
1 year (2020-10-26) 134.90%
2 years (2019-10-25) 288.78%
3 years (2018-10-22) N/A
5 years (2016-10-22) N/A

INmune Bio financials

Revenue TTM $14,916
Gross profit TTM $10,916
Return on assets TTM -28.55%
Return on equity TTM -58.94%
Profit margin 0%
Book value $2.86
Market capitalisation $356.1 million

TTM: trailing 12 months

Shorting INmune Bio shares

There are currently 1.1 million INmune Bio shares held short by investors – that's known as INmune Bio's "short interest". This figure is 13.9% up from 992,024 last month.

There are a few different ways that this level of interest in shorting INmune Bio shares can be evaluated.

INmune Bio's "short interest ratio" (SIR)

INmune Bio's "short interest ratio" (SIR) is the quantity of INmune Bio shares currently shorted divided by the average quantity of INmune Bio shares traded daily (recently around 642050). INmune Bio's SIR currently stands at 1.76. In other words for every 100,000 INmune Bio shares traded daily on the market, roughly 1760 shares are currently held short.

However INmune Bio's short interest can also be evaluated against the total number of INmune Bio shares, or, against the total number of tradable INmune Bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case INmune Bio's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 INmune Bio shares in existence, roughly 60 shares are currently held short) or 0.0957% of the tradable shares (for every 100,000 tradable INmune Bio shares, roughly 96 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against INmune Bio.

Find out more about how you can short INmune Bio stock.

INmune Bio share dividends

We're not expecting INmune Bio to pay a dividend over the next 12 months.

INmune Bio share price volatility

Over the last 12 months, INmune Bio's shares have ranged in value from as little as $7.28 up to $30.37. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while INmune Bio's is 2.8457. This would suggest that INmune Bio's shares are significantly more volatile than the average for this exchange and represent a higher risk.

INmune Bio overview

INmune Bio, Inc. , a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03 that treats patients with advanced cancers with elevated biomarkers of inflammation in their blood; XPro1595 for the treatment of Alzheimer's disease; LivNate to treat patients with non-alcoholic steatohepatitis; and Quellor for cytokine release syndrome and complications of COVID-19. The company has license agreements with Xencor, Inc. ; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc.

Frequently asked questions

What percentage of INmune Bio is owned by insiders or institutions?
Currently 26.669% of INmune Bio shares are held by insiders and 14.652% by institutions.
How many people work for INmune Bio?
Latest data suggests 5 work at INmune Bio.
When does the fiscal year end for INmune Bio?
INmune Bio's fiscal year ends in December.
Where is INmune Bio based?
INmune Bio's address is: 980 North Federal Highway, Boca Raton, FL, United States, 33432
What is INmune Bio's ISIN number?
INmune Bio's international securities identification number is: US45782T1051
What is INmune Bio's CUSIP number?
INmune Bio's Committee on Uniform Securities Identification Procedures number is: 45782T105

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site